Undisclosed B-cell tumor antigen

Undisclosed B-cell tumor antigen is a placeholder term used in pharmaceutical development and clinical trial registries to refer to a proprietary molecular target expressed on the surface of malignant B-cells. This designation is typically employed by biotechnology companies, such as ADC Therapeutics, AbbVie, and Genmab, to protect intellectual property regarding the specific identity of a novel target (e.g., a specific Cluster of Differentiation or CD marker) during early-stage research and Phase 1 trials (ADC Therapeutics Pipeline, 2024; Genmab Annual Report, 2023). These antigens are selected based on their high prevalence in B-cell lineage cancers like Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), while maintaining minimal expression on non-hematopoietic tissues to ensure a favorable therapeutic index. Drugs targeting these antigens are often engineered as antibody-drug conjugates (ADCs) to deliver cytotoxic payloads directly to the tumor or as bispecific antibodies to recruit T-cells for directed cell killing. Because the specific protein is not named, the biological function is generally inferred to involve B-cell maturation, signaling, or survival pathways common to the B-cell lineage.

Other names

Proprietary B-cell antigenUndisclosed B-cell surface proteinNovel B-cell target

Targeted immunotherapy including Antibody-Drug Conjugates (ADCs), Bispecific T-cell Engagers (BiTEs), and Chimeric Antigen Receptor (CAR) T-cell therapies designed to induce selective lysis of malignant B-cells.